Valve disease and pulmonary arterial hypertension due to appetite suppressants (update).
(1) The unfavourable risk-benefit ratio of amphetamine appetite suppressants has led the French medicines agency to withdraw their marketing authorisation.
D000662:Amphetamines / Q000009:adverse effects; D001067:Appetite Depressants / Q000009:adverse effects*; D004053:Diethylpropion / Q000009:adverse effects; D005602:France; D006349:Heart Valve Diseases / Q000139:chemically induced*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D011358:Product Surveillance, Postmarketing; D016896:Treatment Outcome
D000662:Amphetamines; D001067:Appetite Depressants; D004053:Diethylpropion